Skip to main content
Funded Studies

Deniz Kirik, MD, PhD

Professor at Lund University

Location: Lund Sweden

Deniz Kirik, MD, PhD, has over 25 years of experience in development of cell and gene therapy for treatment of neurodegenerative diseases, with special emphasis on Parkinson’s disease. His work involved development of AAV vectors in rodent and non-human primate models. Dr. Kirik made significant contributions cell therapy for PD demonstrating the relationship between the disease severity, integration of the grafted cells in the brain and functional recovery in complex tasks. His findings were instrumental in taking novel treatments in both areas into clinical testing. Dr. Kirik co-authored more than 150 papers and cited more than 17,000 times to date. He was the recipient of prestigious European Research Council (ERC) support in 2009 and 2012, and was recognized as one of 10 achievements in 10 years of the ERC in 2017. He was named the Allan and Maria Myer Fellow in 2010 and has been a regular member of the Science Academy, Istanbul, Turkey since 2015.


Associated Grants

  • Development of a Novel Intracellular Alpha-synuclein-lowering Strategy based on CRISPR Interference Technology

    2019


  • Developing a Reliable Clinical Test for pS129 Alpha-synuclein

    2018


  • Quantification of S129 Phosphorylated Alpha-synuclein Using the AlphaLISA® Immunoassay Platform

    2017


  • Parkin-mediated Mitigation of Neurodegeneration Induced by Overexpression of Alpha-synuclein Using AAV Vectors

    2014


We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.